Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates
Nov. 12, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today reported financial results ...
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the third quarter ended September 30, 2024,
Ceribell Reports Third Quarter 2024 Financial Results
CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions,
GreenFirst Reports Financial Results for the Third Quarter of 2024
TORONTO, ON / ACCESSWIRE / November 12, 2024 / GreenFirst Forest Products Inc. (TSX:GFP) ('GreenFirst' or the 'Company') announced results for
Wave Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced financial results for the third quarter ended September 30,
Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights
AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, to complete enrollment in the first half of 2025Expect to announce topline results
Investor's Business Daily on MSN22d
Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space.
Shares of Korro Bio and Wave Life Sciences sank Monday after an analyst argued the former is the better way to play the ...
Korro Bio’s Promising Regulatory and Preclinical Advances Earn a Buy Rating from Analyst Mitchell Kapoor
H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Korro Bio (KRRO – Research Report) today and set a price target of ...
Fintel on MSN22d
Raymond James Initiates Coverage of Korro Bio (KRRO) with Strong Buy Recommendation
Fintel reports that on October 21, 2024, Raymond James initiated coverage of Korro Bio (NasdaqCM:KRRO) with a Strong Buy ...
ETF Daily News21d
Korro Bio (NASDAQ:KRRO) Price Target Raised to $105.00
Korro Bio stock opened at $70.02 on Monday. Korro Bio has a fifty-two week low of $9.15 and a fifty-two week high of $98.00. The stock’s fifty day moving average is $43.72 and its two-hundred ...
Nasdaq22d
Korro Bio price target raised to $105 from $95 at RBC Capital
RBC Capital raised the firm’s price target on Korro Bio (KRRO) to $105 from $95 and keeps an Outperform rating on the shares. The firm notes that RNA editing data from Wave Life Sciences (WVE ...
Investing19d
Korro Bio's SWOT analysis: RNA editing pioneer's stock poised for clinical leap
Korro Bio, Inc. (NASDAQ:KRRO), a biotechnology company specializing in RNA editing, is making significant strides in the development of genetic medicines, particularly for Alpha-1 Antitrypsin ...
ETF Daily News18d
Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Rating of “Buy” by Analysts
Shares of Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) have been assigned an average recommendation of “Buy” from the six brokerages that are currently covering the stock, MarketBeat reports.
Nasdaq22d
Korro Bio initiated with a Strong Buy at Raymond James
Raymond James initiated coverage of Korro Bio (KRRO) with a Strong Buy rating and $153 price target The firm believes RNA editing will provide better therapeutic modality than DNA editing and/or ...
Investing25d
Korro Bio shares target lifted, buy rating on RNA editing potential
On Friday, H.C. Wainwright updated its outlook on Korro Bio Inc. (NASDAQ:KRRO) shares, increasing the price target to $115 from $100, while maintaining a Buy rating on the company's stock.